Publication biases and phase II trials investigating anticancer targeted therapies

Investigational New Drugs

Volumn 27, Issue 3, 2009, Pages 287-288

  Penel, Nicolas ^a   Adenis, Antoine ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Clinical trial; Impact factor; Methodology; Molecular targeted therapies; Publication biases

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; IMATINIB; SORAFENIB; SUNITINIB;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MEDICAL LITERATURE; MOLECULAR THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PUBLISHING; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NEOPLASMS; PUBLICATION BIAS;

EID: 64649096381     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9186-4     Document Type: Article

References (5)

1. MK Krzyzanowska M Pintillie IF Tannock 2003 Factors associated with failure to publish large randomized trials presented at an Oncology Meeting JAMA 290 495 501
2. R Hall C De Antueno A Webber 2007 Publication bias in medical literature: a review by a Canadian Research Ethics Board Can J Anaesth 54 380 388
3. DS Krause RA Van Etten 2005 Tyrosine kinases as targets for cancer therapy N Engl J Med 353 172 187
4. S Dent B Zee J Dancey A Hanauske J Wanders E Einsenhauer 2001 Application of a new multinomial phase II stopping rule using response and early progression J Clin Oncol 19 785 791
5. MJ Ratain T Eisen WM Stadler 2006 Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 2505 2512